Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban and dabigatran versus acenocoumarol in cerebral venous thrombosis
PACTR202202477162480Phase 4Recruiting
- Sponsor
- Centre Hospitalier Universitaire Hassan II
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in cerebral sinovenous thrombosis (CSVT) comparing Rivaroxaban arm, Dabigatran arm and Acenocoumarol arm (3 arms). Primary endpoints: All-cause mortality, Major bleeding and 1 more. Started Apr 2019; status: recruiting.
02
Drugs
rivaroxabandabigatranacenocoumarol
03
Conditions
cerebral sinovenous thrombosis (CSVT)
Beyond the preview
Go deeper on PACTR202202477162480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202202477162480.